Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Bought by MetLife Investment Management LLC

MetLife Investment Management LLC increased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 3.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 23,452 shares of the company’s stock after acquiring an additional 845 shares during the period. MetLife Investment Management LLC’s holdings in Amphastar Pharmaceuticals were worth $871,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Huntington National Bank grew its holdings in Amphastar Pharmaceuticals by 36.9% in the 4th quarter. Huntington National Bank now owns 1,340 shares of the company’s stock worth $50,000 after buying an additional 361 shares in the last quarter. Bank of Montreal Can increased its stake in Amphastar Pharmaceuticals by 4.6% during the 4th quarter. Bank of Montreal Can now owns 8,215 shares of the company’s stock valued at $305,000 after buying an additional 361 shares during the period. TD Private Client Wealth LLC increased its stake in Amphastar Pharmaceuticals by 22.7% during the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock valued at $78,000 after buying an additional 388 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Amphastar Pharmaceuticals by 222.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after acquiring an additional 493 shares during the period. Finally, KBC Group NV boosted its holdings in shares of Amphastar Pharmaceuticals by 43.1% in the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock valued at $80,000 after acquiring an additional 650 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Trading Up 2.6 %

Shares of NASDAQ:AMPH opened at $24.50 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of 8.17, a PEG ratio of 2.19 and a beta of 0.79. Amphastar Pharmaceuticals, Inc. has a 1-year low of $22.64 and a 1-year high of $53.96. The company has a 50 day moving average price of $26.32 and a 200 day moving average price of $35.77.

Analysts Set New Price Targets

AMPH has been the subject of a number of research analyst reports. Piper Sandler cut their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research report on Friday, March 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th.

Insider Transactions at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the company’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the sale, the chief financial officer now directly owns 97,363 shares of the company’s stock, valued at $2,681,377.02. This represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 5,231 shares of company stock valued at $142,752 in the last three months. 27.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.